Indeed, in the past few years, clinical treatment of BRAF-mutant melanoma patients shifted toward a vertical combination of BRAF and MEK inhibitors, able to determine major improvements in terms of OS and PFS [8,30,31,32,33]. This evidence concerns the gene MAP2K7 and melanoma.